This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MEDNAX Earns $1.32 Per Share For 2012 Third Quarter

Stocks in this article: MD

At September 30, 2012, MEDNAX had cash and cash equivalents of $66.1 million and net accounts receivable were $250.5 million.

During the 2012 third quarter, MEDNAX generated cash flow from operations of $134.7 million. For the nine months ended September 30, 2012, MEDNAX generated cash flow from operations of $219.7 million.

MEDNAX also used $137.5 million of its cash during the 2012 third quarter to fund two anesthesiology and one pediatric cardiology group practice acquisitions and to make contingent purchase price payments for previously completed acquisitions. The anesthesiology group practices are located in Knoxville, Tennessee, and Leesburg, Virginia, while the pediatric cardiology practice is located in Austin, Texas.

A total of 10 physician group practices have been acquired through September 30, 2012, with five physician group practices becoming part of American Anesthesiology and five group practices becoming part of Pediatrix Medical Group.

2012 Fourth Quarter Outlook

For the 2012 fourth quarter, MEDNAX expects earnings will be in a range of $1.27 to $1.32 per share. This range assumes that total same-unit revenue for the three months ended December 31, 2012 will grow by 2.0 percent to 4.0 percent from the prior-year period. This same-unit growth forecast is expected to be divided between approximately one-half patient volume growth across all MEDNAX physician specialties and one-half net reimbursement growth, including improvements from commercial contract rates as well as variability in the mix of services reimbursed under commercial and government payor programs.

Earnings conference call

MEDNAX, Inc., will host an investor conference call to discuss the quarterly results at 10 a.m., E.T. today. The conference call Webcast may be accessed from the Company’s Website, www.mednax.com. A telephone replay of the conference call will be available from noon Eastern Time today through midnight E.T. November 15, 2012 by dialing 800.475.6701, access code 267063. The replay will also be available at www.mednax.com.

ABOUT MEDNAX

MEDNAX, Inc. is a national medical group that comprises the nation's leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services as well as anesthesia services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Pediatrix Medical Group, a unit of MEDNAX, was founded in 1979 and now includes neonatal physicians who provide services at more than 300 neonatal intensive care units, who collaborate with affiliated maternal-fetal medicine, pediatric cardiology and pediatric critical care physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation's largest provider of newborn hearing screens. In 2007, MEDNAX expanded into anesthesia services. Today, American Anesthesiology includes more than 1,200 anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX, through its affiliated professional corporations, employs more than 1,900 physicians in 34 states and Puerto Rico. Additional information is available at www.mednax.com.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”, “plan”, “will”, “expect”, “estimate”, “project”, “positioned”, “strategy” and similar expressions, and are based on assumptions and assessments made by MEDNAX’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in MEDNAX’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well MEDNAX’s current reports on Form 8-K, filed with the Securities and Exchange Commission.

   

MEDNAX, INC.

Condensed Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

 
Three Months Ended

September 30,

Nine Months Ended

September 30,

2012   2011 2012   2011
 
Net patient service revenue $ 473,134   $ 407,665   $ 1,345,280   $ 1,183,350  
Operating expenses:
Practice salaries and benefits 292,030 246,687 840,242 725,873
Practice supplies and other operating expenses 17,606 16,718 52,547 48,061
General and administrative expenses 48,200 43,010 143,269 127,510
Depreciation and amortization   7,925     6,213     22,725     18,026  
Total operating expenses   365,761     312,628     1,058,783     919,470  
Income from operations 107,373 95,037 286,497 263,880
Investment income 422 337 1,215 991
Interest expense   (624 )   (1,056 )   (2,026 )   (2,955 )
Income before income taxes 107,171 94,318 285,686 261,916
Income tax provision   41,261     36,077     110,882     102,278  

Net income

$ 65,910   $ 58,241   $ 174,804   $ 159,638  
 
 
Net income per common and common

equivalent share (diluted)

$ 1.32   $ 1.19   $ 3.53   $ 3.28  

Weighted average shares used in computing net income per common and common equivalent share (diluted)

  49,809     48,935     49,570     48,683  
 

 
Balance Sheet Highlights

(in thousands)

(Unaudited)
   
As of As of
September 30, 2012 December 31, 2011
Assets:
Cash and cash equivalents $ 66,124 $ 18,596
Short-term investments 5,765 4,139
Accounts receivable, net 250,507 230,388
Other current assets 80,410 84,150
Goodwill, other assets, property and equipment   2,130,163   1,935,375
Total assets $ 2,532,969 $ 2,272,648
 
Liabilities and shareholders’ equity:
Accounts payable & accrued expenses $ 224,910 $ 234,535
Total debt 48,349 29,470
Other liabilities   310,601   277,627
Total liabilities 583,860 541,632
Shareholders' equity   1,949,109   1,731,016
Total liabilities and shareholders' equity $ 2,532,969 $ 2,272,648
 




3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs